China’s ABclonal bags $189m in Series D funding co-led by Sequoia Capital China

Life Science

ABclonal Technology, a provider of reagents used in life science research, has raked in 1.2 billion yuan ($189 million) in a Series D round of financing, the investee announced on Wednesday.

The fresh round was jointly led by China Merchants Bank’s CMB International, as well as returning investors Sequoia Capital China, and Lucion Venture Capital, a healthcare industry-led investment firm that has backed startups such as 3D Medicines, RemeGen, and Applied Protein Technology.

Bring stories like this into your inbox every day.

Sign up for our newsletter - The Daily Brief
Subscribe to Newsletter